KRAS and cancer: Increased activation of ERBB1/EGFR as well as of the other ERBB receptors have widespread involvement in cancers (Hynes and MacDonald, 2009; Tebbutt et al., 2013; Wang, 2017) including, it has recently been established, in KRAS-induced lung tumorigenesis (Kharbanda et al., 2020; Kruspig et al., 2018; Moll et al., 2018).